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ABSTRACT
Despite promising candidates for new therapeutic options 
in the treatment of systemic lupus erythematosus (SLE), 
many clinical trials have failed in the past few years. 
The disappointing results have been at least partly be 
attributed to trial designs. With the aim of stimulating new 
developments in SLE trial design, an international open 
space meeting was held on occasion of the European 
Lupus Meeting 2018 in Duesseldorf, Germany about ‘What 
are the topics you care about for making trials in lupus 
more effective?’. The Open Space is a participant- driven 
technology, where the discussion topics and schedule 
are selected during the meeting by all participants 
and discussion rounds are led by the people attending 
encouraging active contributions. Eleven topics were 
selected for further discussion, of which 6 were voted to 
be more intensively discussed in two consecutive rounds. 
Major topics were the optimal handling of glucocorticoids 
in clinical trials, the improvement of outcome measures, 
reducing or controlling the placebo response and the 
identification of biomarkers and stratification parameters. 
Further, the importance of local and international networks 
was emphasised. By networking, collaborations are 
facilitated, patient recruitment is more efficient and 
treatment can be harmonised thus lead to more successful 
SLE trials. Further discussions are needed to substantiate 
the results and develop new trial designs.
INTRODUCTION
During the past few decades, the expectations 
of living with systemic lupus erythematosus 
(SLE) changed substantially for both patients 
and their treating physicians. With life- 
threatening consequences of acute episodes 
becoming less common due to better thera-
peutic options and improved medical care, 
SLE is now considered a chronic condition, 
although with a substantial disease burden 
and risk of impact on lives.1 2 However, due 
to the disease and adverse effects of thera-
pies, life- threatening manifestations for some 
patients or damage and premature death for 
most, are still real.3 4
Across the same period of time, physicians 
have observed the tremendous efficacy of 
biologicals and target- specific drugs in the 
treatment of other rheumatic diseases, such 
as rheumatoid arthritis or spondyloarthritis 
and have hoped for this wave of innovation 
to spill over to SLE, for similar results. So 
far, however, only one drug of many, beli-
mumab, has been approved for use in SLE 
(with failure).5–7 A few novel drugs have now 
completed successful phase III trials.8 9
Although there have been new candidates 
targeting novel pathophysiological concepts, 
many have had disappointing results along 
the path of controlled trials.10 11 Opposite 
experience has occurred in drug develop-
ment in rheumatoid arthritis: most drugs 
reaching the primary endpoint in phase II 
have also passed phase III. With this back-
ground, the results of clinical trials in SLE are 
even more disappointing, and the possible 
reasons and potential alternative post- hoc 
analyses are extensive.
With the aim of stimulating new develop-
ments in SLE trial design, an ‘Open Space’ 
discussion was performed on occasion of the 
European Lupus Meeting 2018 in Duessel-
dorf, Germany, about ‘What are the topics 
you care about for making trials in lupus 
more effective?’. The results are described in 
this report.
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Principles of Open Space
Looking for a meeting technique that stimulates active 
contribution of every participants and allows discussion 
of all important topics present in the group, Open Space 
seemed most appropriate. Open Space is a self- organised 
process that practices inner discipline and collective 
activity and is thought to release the inherent creativity 
and leadership in people. By inviting participants to 
take responsibility for what they care about, Open Space 
intends to establishes a marketplace of inquiry, reflec-
tion and learning, designed to bring out the best in both 
individuals and the whole.12 Open Space is a specific 
method for conferences developed by Owen, which today 
is mostly used in change management, which describes a 
structured approach for organisational changes.13 It has 
been used for clinical conferences before.14
We used the Open Space technology for discussion 
of SLE trials, since the complexity of the disease and its 
treatment requires many stakeholders for a broad input 
and we were seeking an open, participant- driven discus-
sion. Therefore, experts in lupus with great experiences 
in trials were invited and patients’ representatives. As 
the basic intention was free scientific focused discussion 
rounds, other groups involved in drug development as 
government drug approval agencies and pharmaceutical 
industries were not invited.
Speakers of the European Lupus Meeting 2018 were 
invited to the Open Space meeting in English language 
with the topic ‘What are the topics you care about for 
making trials in lupus more effective?’. Twenty- five experts 
(lupus experts, trial methodologists and a vasculitis trial 
expert), two patient representatives of Lupus Europe (the 
European joint organisation of regional lupus patient 
groups) and three local physicians joined the meeting, 
which was moderated by MS who had received a special 
training for Open Space management and organisation. 
It was the first Open Space experience for all participants.
As Open Space is a self- organising process and mainly 
participant- driven. All participants, who had equal rights, 
developed the meeting’s agenda jointly by suggesting 
topics and voting for the preferred ones to discuss 
further. As a basic principle for Open Space, hierarchical 
structures are banned, and all opinions are of equal 
worth. The rules are simple: most important, there is the 
Law of Two Feet, which means every participant takes 
responsibility for what she/he cares about, stands up for 
that and uses his/her own two feet to move to whatever 
place he/she can best contribute and learn. Further, 
four principles apply to how to navigate in Open Space: 
Whoever comes is the right people, meaning that whoever is 
attracted to the same conversation are the people who 
can contribute most to that conversation—because they 
care; Whatever happens is the only thing that could have; When 
it starts is the right time; and When it’s over, it’s over.13 Sched-
uled time for this Open Space gathering was 1.5 days, in 
which four rounds were performed, with three levels of 
discussions each.
The meeting was sponsored by multipurpose arthritis 
centre ‘Rheumazentrum Rhein- Ruhr’, a non- profit 
association.
Discussion rounds
After introductions and an explanation of the Open 
Space concept and rules, the participants identified 
13 topics which were they believed relevant for making 
lupus trials more effective (table 1). Each issue had 
been described by their proponent and similar or 
related ideas were merged, for example ‘biomarkers’ 
and ‘biologically selected patients’ were combined for 
further discussion. The first discussion level took place 
in two consecutive rounds with six topics each. Every 
discussion was structured by two to three guiding stand-
ardised questions (box 1); the content of the exchange 
in every group was open solely developed by the partic-
ipating experts. All discussion processes and results 
were documented on flip charts. After the 12 discus-
sion rounds of 120 min each, the results were presented 
to the whole group and further discussed in plenum. 
Public voting was done as part of the Open Space process 
to select areas for a second and third discussion and 6 
of 12 topics were chosen. In contrast to the first open 
discussion round, rounds 2 and 3 were directed to focus 
on ‘challenges’ and ‘needs for translation into practice’, 
respectively. In the following we present the results of 
each discussion round, with the most important aspects 
visualised in figure 1. Importantly, brainstorming new 
ideas can be inhibited if people feel inhibited or defen-
sive about their suggestion and providing evidence or 
details or even a formal rationale was discouraged from 
Table 1 Discussion topics identified as relevant to discuss 
in the first, second and third discussion round




First session Glucocorticoids 18 +
Outcomes 16 +
Stratification 16 +















*Biomarkers and biologically selected patients were two different 
topics that were fused by the participants.
†No participant (law of two feet).
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the beginning. Hence, we refrain from literature quota-
tions in the Results section and present eminence- based 
opinions and facts.
Glucocorticoids—how to reduce oral steroids?
As in many other lupus meetings, the use of gluco-
corticoids (GC) in trials was selected as an important 
topic of discussion, due to their significant impact on 
outcomes and the need to avoid the harm associated 
with their use. In the first round, the aspects ‘need for 
maintenance therapy’, ‘what is the safe dose—if there 
is one?’, ‘how to treat flares—with pulse or oral dose?’ 
and ‘tapering schemes’ were identified as most impor-
tant. As a result of the discussion, three study designs 
were developed: (1) A controlled withdrawal trial of 
GC with standardised documentation of clinical signs, 
symptoms and patient- reported outcomes (PRO); bio- 
specimens should be taken at several time- points to 
identify predictors of flares posthoc. (2) A randomised 
controlled trial (RCT) to evaluate short term pulse vs 
oral dose GC with the outcomes Definition of Disease 
Remission (DORIS) remission,15 Lupus Low Disease 
Activity State (LLDAS)16 and PROs. (3) Trial to compare 
a fixed GC tapering protocol to GC reduction according 
to the treating physicians’ discretion.
At the end of the first discussion round, agreement on 
standardised GC doses for pulses and tapering protocols 
as well as the definition of a right starting point for both 
tapering and GC withdrawal were still pending and seen 
by the group as challenges.
In the subsequent discussion rounds on GC, the need 
of optimising GC use was reaffirmed and the solutions to 
‘how to treat flares’, ‘pulse vs oral therapy’, ‘optimal dose’ 
and ‘lowest GC dose’ were identified as crucial. Further-
more, in search of the ideal outcome for trials on GC, 
‘time to flare’ and ‘cumulative GC dosage’ were chosen.
As the most important next step, the group recom-
mended an ambitious GC protocol to treat flares and/or 
disease activity with no or only minimal damage and good 
quality of life (QoL) as the result. To design this trial, a 
literature search on GC use (pulses or oral) to treat flares 
was recommended and GC doses in patients in RCTs and 
in daily care should be analysed. Therefore, surveys on 
clinical practice should be performed or retrieved from 
existing data. Based on these data, an expert consensus 
trial protocol should be developed.
Finally, low flexibility of healthcare providers and 
authorities in changing the paradigm in GC use was seen 
as the most important unsolved issue in clinical trials. The 
challenge will be to find the balance between conclusions 
drawn from data, physicians’ and patients’ viewpoints and 
disease variability.
Outcomes
Organ specific manifestations, remission and LLDAS, 
PROs, new measures and especially challenges around the 
Box 1 Specific questions addressed in each discussion round
Guiding question:




 ► What aspects have been discussed with regards to our topic and 
why?
 ► What are our main results?
 ► Which open issues/challenges do we face?
Second
 ► Identify urgent needs and their rationale.
 ► Which open issues/challenges do we face?
Third
 ► What is needed for the successful implementation of the identified 
urgent needs?
 ► What could be the next steps and who should be addressed?
 ► Which open issues/challenges do we face?
Figure 1 Aspects and contexts identified as relevant in SLE trials. PRO, patient- reported outcomes; SLE, systemic lupus 
erythematosus.
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existing trial endpoint, SRI, were extensively discussed. 
Joint counts (tender and swollen), EULAR/ACR 
response definitions for lupus nephritis (excluding red 
blood count in urinary sediments) and Cutaneous Lupus 
Erythematosus Disease Area and Severity Index (CLASI) 
as a skin score were supported as possible organ specific 
outcomes. For non- organ specific outcomes like global 
disease activity or fatigue, the participants expressed 
the need for a new outcome variable. Remission, as it is 
defined by DORIS criteria, was felt to be better applicable 
for long- term studies, not as a primary outcome in RCTs. 
LLDAS was considered suitable for RCTs, although for 
some individuals, low disease activity may not be suffi-
cient. Regarding SRI, the experts saw limitations mainly 
due to the SLE Disease Activity Index's (SLEDAI) insen-
sitivity to change and the imbalance of response due to 
different SLEDAI domain weights. A combination of 
the SLE responder index 4 (SRI-4) with GC tapering 
was discussed as a potential composite measure. Such an 
approach would require standardising GC tapering, as 
the true challenge lies in different attitudes to reducing 
GC.
Based on the above stated limitations for commonly 
used outcome measures, the group identified an urgent 
need for new trial outcome(s). As a first modification, 
the change from measuring outcomes at a single time 
point to reaching a stable outcome over a certain period 
of time, ideally over the last period of a trial, was recom-
mended. Regarding the type of measure, a continuous 
measure was preferred, which should take into account 
different grades of disease activity in each organ, such 
as the DAS-28 does in rheumatoid arthritis. The new 
activity index for trial outcome should summarise single- 
point organ specific complete or partial improvements 
with persistent response. For the implementation of a 
continuous activity index, defining thresholds of remis-
sion and LLDAS was seen as an option. The currently 
defined DORIS remission and LLDAS criteria were 
considered unsuitable for the ‘usual’ 52 weeks trials. 
PROs should be included into the outcome measure 
and GC should be reduced to unmask drug efficacy. The 
majority of the group believed that the ideal outcome 
should include physician and patient global assessment 
as well as low GC dosage.
Outcome instruments that meet the mentioned 
criteria should be validated in cohort studies as well as by 
applying them to datasets from clinical trials, particularly 
failed RCTs, and should then be tested in clinical care. 
The experts recommended that the validation should be 
a network approach, for example, by SLEuro, with the 
inclusion of recommendations for outcomes by a EULAR 
taskforce. The results will need to be discussed with 
drug licensing agencies (FDA and EMA) in order to be 
included into RCTs for new drugs.
At the end of the discussion, open issues for further 
discussion were a remission based on tissue samples 
(proof- of- concept trial), modifications of immunological 
pathways and other outcomes that might allow a smaller 
number of patients for evaluation.
Patient/disease subsets—patient stratification
The heterogeneity of disease expression in SLE is gener-
ally seen as a major challenge for all trials. Classifica-
tion criteria were developed as the first step to recruit 
a more homogenous population. The group discussed 
and recommended exploring alternative stratification 
methods like lupus nephritis versus non- renal SLE, based 
on single organ involvement or on disease patterns (eg, 
according to flares), on biomarkers (eg, conventional 
or interferon (IFN) signature), on baseline or historic 
characteristics, or on comorbidities and disease manifes-
tations. Stratification should also consider background 
therapy.
To bring together all these aspects of stratification, 
the challenge will be to design several studies within 
the framework of one big trial. New, valid and reliable 
biomarkers would be a prerequisite for improved strati-
fication methods. In such a master protocol, in addition 
to the conventional stratification to renal or extrarenal 
lupus, extended lupus nephritis strata categories could 
include new disease manifestation versus lupus nephritis 
flare versus refractory lupus nephritis, renal chronicity, 
ethnicity and potentially move away from the focus on 
just Class III and IV nephritis. Stratification of extrarenal 
lupus should be domain- specific. For example, there 
should be a differentiation between acute, subacute and 
discoid lupus skin manifestations and non- erosive, erosive 
and Jaccoud’s arthropathy for arthritis. Other relevant 
parameters might be overall disease activity, disease 
duration or geographical region. In addition, creative 
approaches might include molecular signatures and 
biomarkers based on pathophysiology.
At this point in the discussion, concerns were expressed 
that such novel designs would not fit into current conser-
vative regulatory policies and that insufficient stratifica-
tion was the real problem of the past trial failures. To 
further explore this issue, a query of study databases 
(both failed and successful) is necessary, in which single 
organ domain trials and single organ parts of other 
studies should be analysed. In addition, the proposed 
master protocol needs discussion with regulatory author-
ities and (commercial) sponsors. For a better acceptance 
of such a protocol, it would be helpful to declare the 
subtypes of lupus, for example, lupus nephritis, as an 
orphan disease to minimise the burden of trials. Probably, 
the term ‘rare and complex disease’ would be helpful as 
successfully used in the European Reference Networks 
(ERN). Furthermore, an expert consent on reclassifica-
tion of more homogeneous subsets of lupus would be 
quite beneficial.
The still pending issue from this discussion was whether 
sponsors would be willing to invest the necessary budget 
to develop drugs for rare diseases or for life- threatening 
cases to facilitate the approval process.
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Basket trial in SLE
In a basket trial design, patient eligibility is defined by 
a particular biomarker or molecular alteration, and a 
specific disease itself, for example, a specific tumour 
type, is not a primary inclusion criterion. In such studies, 
biological profiles, for example, C4 complement defi-
ciency in systemic connective tissue diseases (CTDs), 
would be linked to response and non- response to a 
specific intervention. Basket trials have just begun in 
cancer therapy. In rheumatology, no such trial has been 
done. The group discussed the benefits of basket trials 
such as potentially smaller sample sizes, a shorter dura-
tion and to be more powerful than conventional trials, 
with the effect size driving the design. The pathway 
related to the targeted biomarker or molecular alteration 
offers a specific readout, which might even be specific for 
individual organs. Analyses during the trial would enable 
early detection of responses and drug resistance and facil-
itate prompt adaption of treatment.
In lupus or CTDs in general, the first challenge to 
design a basket trial will be to identify a suitable target 
accessible for intervention and present in a group of 
patients. Further needs are stable and reproducible 
signature(s) across CTDs, innovative drugs that match 
the signature, common clinical criteria for entry across 
diseases and adapted response criteria (across diseases 
vs organ specific response vs holistic response). Finally, 
FDA/EMA would have to approve the design for a new 
indication in SLE; a design that would be unprecedented 
and highly challenging.
Discussions with oncologists, information scientists and 
clinicians could be a next step. In parallel, high quality 
proteomic and genomic data from CTDs should be 
screened for signatures and alterations that could serve 
as inclusion criterion in a basket trial. Drugs with proven 
pharmacodynamic effect on the specific molecular 
pathway need to be identified or even newly designed.
Recruitment
Recruitment has been a critical challenge in every SLE 
trial, in particular the pool of eligible patients is small and 
recruitment often slower than estimated.
In this discussion, led by experts and patients, how to 
improve recruitment and retention of eligible patients was 
the dominant focus. The patients’ motivation to partic-
ipate in a trial is mostly intrinsically driven by the hope 
to get a new treatment and better care and by the feeling 
of being a part of something bigger. Further discussed 
challenges were the patients’ adherence to treatment and 
the burden of frequent assessments in trials combined 
with distance. Financial allowances for patients were also 
debated.
The discussants agreed on the need for a network 
approach in conducting trials. Instead of single site trials, 
studies practically require multiple sites with clinics, 
private practices and patient organisations that actively 
participate. Such a network could improve awareness of 
existing trials and increase the pool of eligible participants 
due to ‘patient sharing’. Ideally, the patients would be 
entered into a registry and their information would be 
accessible for study personnel.
The networks could organise information campaigns 
on ongoing trials and help to create a positive perception 
of trials, in order to increase willingness to participate. 
Furthermore, general education of patients on adher-
ence and their responsibilities and duties in clinical trials 
were stressed. These would hopefully reduce patients’ 
concerns and eliminate fears of participating. In addi-
tion, less negative perception of trials could also reduce 
the placebo/nocebo responses since expectations might 
be less strong. All participants in the group (lupus experts 
and patients) demanded that patients be part of the trial 
team and not seen only as a test subject. Words of grati-
tude and information about trial results would be highly 
appreciated, and the consensus of the discussion was that 
these should be distributed after trial completion.
Further, the group agreed on a change of perspective: 
Instead of bringing patients into trials, the trials should be 
brought to the patients. Assessment at the patient’s home 
or at least within short distance of home at a network site 
would reduce the burden of trials. Modern communica-
tion technologies will hopefully soon facilitate offering 
such options.
Major concerns regarding network trials were raised 
with a particular focus on legal obligations and the fear 
of opposition to the sharing of data. In addition, funding 
would have to be rearranged and clarified.
As next steps on the way to improve patient recruitment, 
the discussants agreed on the need of raising awareness, 
promoting the concept, content and necessary funding 
at pharmacological and state agencies and establishing 
a registry (eg, European- wide) with adequate partners 
(eg, ERN, SLEuro). Patients need to be integrated in all 
steps and should be supported to play an active role as a 
partner within the network.
Reduce the placebo response rate (entry criteria)
The observed placebo (PBO) responses in SLE are as 
much as twice those of trials of rheumatoid arthritis and 
psoriatic arthritis. Interestingly, PBO response seems 
to be lower in extrarenal trials than in lupus nephritis 
studies. A high PBO response lowers the effect size and 
ceiling effects are predicted. Recommendations from the 
group on reducing PBO rates were quite clear:
 ► exclude patients without classified SLE,
 ► omit ‘soft’ SLEDAI items, for example, alopecia, 
ulcers and inflated SLEDAI scores (elevated due to 
unspecific symptoms such as headache, arthralgia),
 ► omit items difficult to improve with therapy (eg, 
blood alterations such as white blood cell and platelet 
count),
 ► document findings for example, by photographs of 
skin findings or sonography for joints,
 ► add biomarkers as inclusion criteria, such as autoanti-
body titres, low complement, IFN- signature,
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 ► move to domain specific measurements, for example, 
CLASI or joint counts,
 ► omit centre of high placebo response,
 ► measure drug levels during screening to exclude non- 
compliant patients,
 ► optimise background therapy,
 ► stop all background medications after 3 months as an 
optional concept
Without a doubt, these suggestions pose several chal-
lenges: Recruitment is becoming more difficult with 
stricter entry criteria, optimisation or stopping of back-
ground therapy will raise ethical issues and might result 
in lower recruitment and response rates, and marketing 
concerns by sponsors due to drug approval only for SLE 
subgroups might hinder drug development.
Designing trials with a drug stop phase
The topic of trials design with a ‘drug stopping phase’ 
overlapped with other discussion rounds and focused 
mainly on the improvement and new development of 
trial designs to reduce costs and improve efficiency. A 
drug stop design could be an option for non- severe cases 
in the maintenance phase of an early disease; probably 
most important these patients should be homogenous 
in disease expression. In addition, simpler measures and 
outcomes could facilitate such trials that otherwise should 
be performed in centres with expertise.
Biomarkers; selection of biologically selected patients for 
targeted therapies
Despite being addressed in several of the other rounds, 
there was an extra discussion on biomarkers only, empha-
sising their great perceived importance regardless of 
previous disappointing results. The potential relevance of 
biomarkers for improving diagnostics, predicting flares 
and changes in disease activity and monitoring, confirming 
or predicting treatment responses was discussed. For now, 
IFN- signature, histological findings, CD19+ B cell counts, 
antibodies (eg, anti- dsDNA, anti- C1q, anti- phospholipid 
antibodies) and complement deficiencies were named 
as classical candidates. It was stated that to date, no reli-
able biomarkers found general applicability, with urine 
biomarkers being the most promising candidates. Since 
no patient is like another, it was highly recommended to 
evaluate synergistic markers or sets of biomarkers and 
their predictive value regarding therapeutic response 
longitudinally.
Finding the difference that is relevant for patients or 
caregivers
This specific discussion on outcomes was mostly driven 
by the perceived vagueness of the connection between 
currently used trial endpoint and patient outcomes. It 
was agreed that patients should be included in trial devel-
opment from the beginning and that their expectations 
regarding a successful trial outcome should be imple-
mented in the design. An option could be the general 
inclusion of PROs as outcome parameters to capture the 
patient- centred (vs clinician- measured) part of the treat-
ment response (‘how are you’). In addition, the severity 
of (severe) adverse events should be indicated by the 
patients.
How to bridge the efficacy-effectiveness-gap?
Efficacy refers to the true biological effects of a drug, that 
is, addressing the question whether and how it actually 
works in a patient. Usually, the efficacy of a new drug 
is studied in clinical trials. In contrast to efficacy, effec-
tiveness describes the extent to which a drug achieves 
its intended effect in the real- world clinical setting, that 
is, improvement in health in everyday practice. The 
improvements of patients’ outcomes achieved in clinical 
trials (efficacy) are often higher than those in everyday 
routine care (effectiveness). This led to the coining of the 
term ‘efficacy- effectiveness- gap’. During the Open Space 
gathering, the discussants developed ideas on how to 
measure effectiveness. Suggestions were conducting prag-
matic trials, using claims data or running and analysing 
lupus registries. Relevant outcomes include quality of 
life, for example, Lupus Quality of Life questionnaire 
(LupusQoL) and measures for disease activity. Discus-
sants emphasised the discordance of PROs and disease 
activity and it was generally questioned whether effective-
ness was a good concept in all situations. The answer to 
that remains open for further discussions.
Oncology type trials in early cases
This discussion round aroused from a similar idea to the 
basket trial discussion. New designs, cost reductions and 
improved efficacy are urgently needed in lupus trials. 
Patients with early disease as a well- defined target popula-
tion should be included in trials adapted from oncology 
with the primary aim of GC sparing. Crossover and ‘stop 
and watch’ designs were discussed as well as an ‘aggres-
sive’ induction for these patients, for example, an anti- B 
cell therapy. Challenges of such trials will be to define 
the target population, to perform trials for single organ 
manifestations and the scant information that is available 
regarding the consequences of stopping treatment in 
lupus.
Activity measurement
The discussion round on activity measures did not take 
place as no one participated. We assume that this topic 
was considered too extensive to be discussed in the time 
available. Nonetheless, the authors consider it highly 
important for clinical trials.
CONCLUDING REMARKS
Despite great success in decreasing the standard mortality 
rate of patients with SLE over the last few decades, the 
current plateau in mortality and the high burden of the 
disease indicate an urgent need for new therapeutic 
options and a better use of already available drugs.1 In the 
last few years, many promising medications failed to pass 
the hurdles of phase II and III clinical trials, preventing 
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drug approval. Intensive discussions and explorations 
of trial failures are ongoing,12 17 18 and as a result, a few 
modifications in trial design were seen in recent phase II 
trials. The results of currently ongoing phase III trials will 
finally show whether these changes were efficient.
Our Open Space discussion raised some issues that 
the field has been discussing without good solutions for 
quite some time. The ideal GC dose, how to treat flares, 
tapering GC (‘lowest dose’) and the stopping of GC are 
on top of this list. The optimisation of other background 
medications should be included in this context. It was 
recommended that the GC dose should also be included 
as part of the primary outcome.
Although no expert was keen to join the discussion on 
‘activity measurements’, which thus did not take place 
according to Open Space rules, this topic was addressed 
in many other discussion rounds. Evaluation of the effi-
cacy of newly developed drugs on disease activity should 
exclude soft SLEDAI items like alopecia and ulcers as well 
as altered serological parameter that may not be related 
to disease activity. Several discussions were in favour of 
using organ- specific indications as primary outcomes in 
trials. In general, the definitions of organ involvement 
and organ- specific treatment response need to be better 
specified and carefully documented, for example, with 
ultrasound imaging and differentiation between the 
various types of joint involvements.
A set of biomarkers, at best monitoring the mode of 
action of the evaluated drug, should be included as an 
exploratory part of every trial. Biomarkers and molec-
ular signatures form the basis for new trial designs such 
as basket trials, which open up another possibility to 
broaden the patient population of a trial. In a next step, 
interdisciplinary discussion rounds with oncologists, 
immunologists and other specialists as well as informa-
tion scientists and clinicians are needed, as well as high 
quality proteomic and genomic data from CTDs. Further, 
drugs with proven pharmacodynamic effects on previ-
ously identified molecular pathways need to be identified 
or developed and tested.
Many of these ideas, proposals and hypotheses can 
be evaluated in a first step by using data from previous 
lupus trials. One major challenge will be to find a balance 
between the conclusions drawn from the data, the clini-
cians’ and patients’ point of view, and the disease.
In addition to these recommendations addressing 
trial design, we identified several pretrial issues and the 
context of clinical trials as highly relevant for successful 
lupus trials. Of these, networking was a major topic. It 
starts locally with networks combining different levels of 
care to aid patient recruitment and standardise care of 
patients with SLE outside trials. A continuous exchange 
within these networks based on guidelines and recom-
mendations should also include empowered patients 
educated in research and development as partners. Local 
networks should join bigger networks based on stan-
dardised documentation, for example, in registries. Such 
a system will facilitate recruitment of patient populations 
with a better documented disease expression and lead to 
a harmonisation of patients’ therapy, which would poten-
tially result in more standardised background medication 
in trials.
If such networks were established worldwide, differ-
ences between various geographical regions, such as in 
placebo responses, could be reduced. Variation in care 
could be reduced by decision support systems, bench-
marking and most importantly by consensus processes 
for standardisation. Those could lead to a paradigm shift 
in GC use towards a more homogenous handling of GC 
in routine care, which will significantly impact GC use in 
trials.
Such networking—locally, nationwide or even world-
wide—is obviously challenging and needs support from 
organisations that combine their efforts. Thinking ahead, 
it could be the basis for successful trials in lupus and for 
a lower disease burden. Both these outcomes serve the 
same purpose, which is to improve the lives of patients 
with lupus.
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